3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Breast Neoplasms
4
Triple Negative Breast Neoplasms
2
Leukemia, Myelomonocytic, Chronic
2
Primary Myelofibrosis
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Hodgkin Disease
1
Hematopoietic and Lymphatic System Neoplasm
1
Cholangiocarcinoma
1
Interventions
Cyclophosphamide
165
fludarabine phosphate
110
Peripheral Blood Stem Cell Transplantation
94
Mycophenolic Acid
88
Whole-Body Irradiation
81
Etoposide
81
Tacrolimus
73
Busulfan
68
Melphalan
67
Filgrastim
66
fludarabine
62
Radiotherapy
56
Doxorubicin
54
Cyclosporine
54
Rituximab
50
Brentuximab Vedotin
48
Antilymphocyte Serum
47
Granulocyte Colony-Stimulating Factor
42
Vinblastine
41
Methotrexate
38
Dacarbazine
37
Cytarabine
35
Gemcitabine
34
Nivolumab
30
Bleomycin
29
Carmustine
28
Vincristine
25
Prednisone
25
Sirolimus
24
Bendamustine Hydrochloride
23
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hodgkin Disease
×
axatilimab
×
Clear all
NCT05723055
2026-05-08
NAHL
University of Utah
Phase 2
Active not recruiting
9 enrolled